Substance P-Induced Migraine Attacks Without Aura

Last updated: June 1, 2025
Sponsor: Danish Headache Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Pain

Oral Facial Pain

Pain (Pediatric)

Treatment

Placebo

Substance P

Clinical Study ID

NCT06959004
H-23034165
  • Ages 18-65
  • All Genders

Study Summary

Substance P is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether its administration can trigger migraine attacks in individuals with migraine without aura.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 to 65 years of age upon entry into screening

  • A body weight of 50 to 100 kg

  • History of migraine without aura for ≥12 months and in accordance with ICHD-3

  • Between 1-5 monthly migraine days without aura on average across the 3 months priorto screening

Exclusion

Exclusion Criteria:

  • Any history of a primary or secondary headache disorder other than migraine withoutaura and infrequent episodic tension-type headache

  • Any history of moderate to severe traumatic brain injury

  • Any history of cardiovascular disease, including cerebrovascular diseases

  • Any history of pulmonary disease

  • Any other clinically significant disorders, conditions, or diseases that mightimpact the safety of the subject or interfere with the study's evaluation,procedures, or completion, aside from those mentioned above. This includes anyrelevant medical history or evidence that, in the opinion of the site investigator,might pose a risk to the subject or impact the validity of the study results

  • The subject is at risk of self-harm or harm to others as evidenced by past suicidalbehavior

  • Female subjects of childbearing potential with a positive pregnancy test during anystudy visit

  • Cardiovascular disease of any kind, including cerebrovascular diseases

  • Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressureof ≥100 mmHg) prior to the start of infusion on the experimental day

  • Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)

  • Daily use of any medication other than contraceptives

  • Intake of any medication other than contraceptives within 48 hours of infusion start

  • Headache of any intensity within 48 hours of infusion start

  • Migraine attack within 5 days of infusion start

  • Aura within 48 hours of infusion start

Study Design

Total Participants: 21
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
May 13, 2025
Estimated Completion Date:
December 01, 2026

Study Description

Substance P is a vasoactive neuropeptide of the tachykinin family, expressed in various cell types, including primary afferents of the trigeminal ganglion that innervate the meninges and associated vasculature. Its most well-established role is in nociceptive signaling, and accumulating evidence implicates substance P in the pathogenesis of headache. This study investigates whether intravenous infusion of substance P can induce migraine attacks in individuals with a history of migraine without aura. To test this, the investigators will conduct a randomized, double-blind, placebo-controlled, two-way crossover trial.

Connect with a study center

  • Rigshospitalet Glostrup

    Glostrup, 2600
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.